Nov 19, 2019
Novo Nordisk has announced to enter into a collaboration with Dicerna’s RNAi platform to focus on metabolic and liver-related diseases. The companies will be focusing to advance the treatment landscape of the diseases such as non-alcoholic steatohepatitis (NASH), Type 2 diabetes and obesity. Nordisk will be inv...
Read More...
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Newsletter/Whitepaper